WO1993012814A3 - Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations - Google Patents

Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations Download PDF

Info

Publication number
WO1993012814A3
WO1993012814A3 PCT/US1992/011159 US9211159W WO9312814A3 WO 1993012814 A3 WO1993012814 A3 WO 1993012814A3 US 9211159 W US9211159 W US 9211159W WO 9312814 A3 WO9312814 A3 WO 9312814A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
pathology
tcr
vaccine
vaccines
Prior art date
Application number
PCT/US1992/011159
Other languages
French (fr)
Other versions
WO1993012814A2 (en
Inventor
Mark D Howell
Steven W Brostoff
Dennis J Carlo
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Priority to JP5511865A priority Critical patent/JPH07506563A/en
Priority to EP93902714A priority patent/EP0623025A1/en
Publication of WO1993012814A2 publication Critical patent/WO1993012814A2/en
Publication of WO1993012814A3 publication Critical patent/WO1993012814A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides vaccines and a means of vaccinating a vertebrate so as to prevent or control specific T cell mediated pathologies, including autoimmune diseases and the unregulated replication of T cells. The vaccine is composed of a T cell receptor (TCR) or a fragment thereof corresponding to a TCR present on the surface of T cells mediating the pathology. The vaccine fragment can be a peptide corresponding to sequences of TCRs characteristic of the T cells mediating said pathology. Such a peptide can bind to conventional antigens complexed to MHC antigen presenting cells or to superantigens. Means of determining appropriate amino acid sequences for such vaccines are also provided. The vaccine is administered to the vertebrate in a manner that induces an immune response directed against the TCR of T cells mediating the pathology. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. The invention additionally provides specific β-chain variable regions of T cell receptors, designated Vβ3, Vβ4, Vβ12, Vβ14 and V, β17, which are associated with the pathogenesis of autoimmune diseases, such as rheumatoid arthritis (RA) and multiple sclerosis (MS). Also provided are means to detect, prevent and treat RA and MS. Methods of administering DNA or RNA encoding the polypeptides useful as vaccines of the present invention into the tissue cells of an individual is also provided.
PCT/US1992/011159 1991-12-24 1992-12-21 Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations WO1993012814A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP5511865A JPH07506563A (en) 1991-12-24 1992-12-21 Vaccination and methods for diseases caused by pathogenic responses by specific T cell populations
EP93902714A EP0623025A1 (en) 1991-12-24 1992-12-21 Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81386791A 1991-12-24 1991-12-24
US813,867 1991-12-24

Publications (2)

Publication Number Publication Date
WO1993012814A2 WO1993012814A2 (en) 1993-07-08
WO1993012814A3 true WO1993012814A3 (en) 1993-09-30

Family

ID=25213619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/011159 WO1993012814A2 (en) 1991-12-24 1992-12-21 Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations

Country Status (5)

Country Link
EP (1) EP0623025A1 (en)
JP (1) JPH07506563A (en)
AU (1) AU3418893A (en)
CA (1) CA2126686A1 (en)
WO (1) WO1993012814A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5667967A (en) * 1990-05-01 1997-09-16 The Board Of Trustees Of The Leland Stanford Junior University T-cell receptor varible transcripts as disease related markers
US6464978B1 (en) * 1989-03-21 2002-10-15 The Immune Response Corporation Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
US6413516B1 (en) * 1989-03-21 2002-07-02 The Immune Response Corporation Peptides and methods against psoriasis
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
AU4529793A (en) * 1992-06-08 1994-01-04 Colorado State University Research Foundation Endogenous ligands for cdr4 of t-cell receptor beta -chains and genes encoding the same
AU695801B2 (en) * 1993-09-22 1998-08-20 Board Of Trustees Of The Leland Stanford Junior University Interaction of T-cell receptors and antigen in autoimmune disease
US6379670B1 (en) 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO1996021028A2 (en) * 1995-01-03 1996-07-11 Procept, Inc. Soluble heterodimeric t cell receptors and their antibodies
LT4475B (en) * 1997-02-28 1999-02-25 Virmantas Stunžėnas Use of the i-rna in the pharmaceuticals for increasing of the amount of protein encoded by said rna in patient cells
AU5528198A (en) * 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
AU5906099A (en) * 1998-09-04 2000-03-27 Baylor College Of Medicine T cell peptides as therapeutics for immune-related disease
BR0008966A (en) 1999-02-23 2002-10-15 Baylor College Medicine T cell receptor vbeta-dbeta-jbeta sequence and processes for its detection
US6541608B1 (en) 1999-02-23 2003-04-01 Baylor College Of Medicine T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011294A1 (en) * 1989-03-21 1990-10-04 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
WO1991001133A1 (en) * 1989-07-19 1991-02-07 Arthur Allen Vandenbark T cell receptor peptides as therapeutics for autoimmune and malignant disease
WO1991015225A1 (en) * 1990-03-30 1991-10-17 Brigham And Women's Hospital Multiple sclerosis t-cell receptor
WO1992012996A2 (en) * 1991-01-22 1992-08-06 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011294A1 (en) * 1989-03-21 1990-10-04 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
WO1991001133A1 (en) * 1989-07-19 1991-02-07 Arthur Allen Vandenbark T cell receptor peptides as therapeutics for autoimmune and malignant disease
WO1991015225A1 (en) * 1990-03-30 1991-10-17 Brigham And Women's Hospital Multiple sclerosis t-cell receptor
WO1992012996A2 (en) * 1991-01-22 1992-08-06 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY vol. 62, no. 1(1), January 1992, NEW YORK, US pages 1 - 7 S. BROSTOFF ET AL. 'T cell receptors, immunoregulation, and autoimmunity.' *

Also Published As

Publication number Publication date
JPH07506563A (en) 1995-07-20
CA2126686A1 (en) 1993-07-08
AU3418893A (en) 1993-07-28
WO1993012814A2 (en) 1993-07-08
EP0623025A1 (en) 1994-11-09

Similar Documents

Publication Publication Date Title
WO1992012996A3 (en) Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
WO1993012814A3 (en) Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
Willenborg et al. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis.
Xu et al. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells
Ober et al. Vaccine-induced, pseudorabies virus-specific, extrathymic CD4+ CD8+ memory T-helper cells in swine
Tanaka et al. A pivotal role of IL-12 in Th1-dependent mouse liver injury
Ohkusu et al. Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection
Janeway Immunogenecity signals 1, 2, 3... and 0
Matis et al. Major histocompatibility complex-linked specificity of γδ receptor-bearing T lymphocytes
Lafaille The role of helper T cell subsets in autoimmune diseases
Iwakura et al. Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans.
RU2136697C1 (en) Method of oligopeptide producing
Harandi et al. Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity
Thomas et al. CD8 T cells inhibit IgE via dendritic cell IL-12 induction that promotes Th1 T cell counter-regulation
Tripp et al. Secondary response to Listeria infection requires IFN-gamma but is partially independent of IL-12.
Kumar et al. Induction or protection from experimental autoimmune encephalomyelitis depends on the cytokine secretion profile of TCR peptide-specific regulatory CD4 T cells
Palendira et al. Coexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobacterium tuberculosis
Letscher-Bru et al. Protective effect of vaccination with a combination of recombinant surface antigen 1 and interleukin-12 against toxoplasmosis in mice
KR920700674A (en) Vaccinations and Methods for Diseases arising from Inventive Responses by Specific T Cell Populations
Melms et al. Autoimmune T lymphocytes in myasthenia gravis. Determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene.
Von Boehmer CD4/CD8 lineage commitment: back to instruction?
Murray et al. Functional CD4 T cell subset interplay in an intact immune system.
Falk et al. Induction and suppression of an autoimmune disease by oligomerized T cell epitopes: enhanced in vivo potency of encephalitogenic peptides
Min et al. Neonatal exposure to a self-peptide–immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin 4 lymph node deviation and interferon γ–mediated splenic anergy
Kariyone et al. Immunogenicity of Peptide‐25 of Ag85B in Th1 development: role of IFN‐γ

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NZ PL RO RU SD

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MG MN MW NZ PL RO RU SD

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2126686

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993902714

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993902714

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993902714

Country of ref document: EP